Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Redcliffe Labs Announces Leadership Transition to Drive Healthcare Accessibility

Home
/
update
/
details

FDA Clears Abbott's Over-the-Counter Continuous Glucose Monitors

NextEdge Admin

11 Jun 2024

1 min 48 sec

Abbott has announced the FDA clearance of two new over-the-counter continuous glucose monitors (CGMs), catering to different segments of the population. The Lingo targets health-conscious consumers, offering insights into metabolism through tracking glucose levels in interstitial fluid. Designed as a wellness device, it provides data on reactions to food, exercise, and stress via a smartphone app, but isn't meant for diagnosing metabolic disorders.

On the other hand, the Libre Rio targets Type 2 diabetics who manage their condition without insulin. Monitoring glucose ranges from 40 to 400 mg/dL, it aids in lifestyle management. Abbott isn't alone in this venture; Dexcom's Stelo CGM, also FDA-cleared, targets the same demographic.

The significance of these OTC CGMs lies in their improved accessibility. Unlike traditional CGMs requiring prescriptions, these are available directly to consumers. This accessibility could benefit individuals with prediabetes or Type 2 diabetes by providing a means to monitor lifestyle changes' impact. Startups like Nutrisense and Levels extend their CGM use to non-diabetics, targeting weight loss, athletic performance, and metabolic health improvement. However, the effectiveness of CGM use in non-diabetic populations remains uncertain.